Gilead Sciences, Inc.

Gilead Sciences to Present at the NASDAQ OMX 23rd Investor Program

Business Wire (Free subscription) | 11/24/2009

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that the company will be webcasting its corporate presentation at the NASDAQ OMX 23rd Investor Program in London. Kevin Young, Gilead’s Executive Vice President of Commercial Operations, will provide an overview of the company at the NASDAQ OMX Investor Program on Tuesday, December 1 at 10:15...

GlaxoSmithKline, Gilead to sell hepatitis B drug in Asia

The Triangle Business Journal (Free subscription) | 11/24/2009

Gilead Sciences Inc. and GlaxoSmithKline on Tuesday announced an agreement to commercialize Viread for the treatment of chronic hepatitis B infection in adults in five countries in Asia. (GSK)

• Gilead in Asian deal for hepatitis B drug - bizjournals
• Gilead and GlaxoSmithKline Announce Agreement to Commercialize Viread® for Chronic Hepatitis B in Key Asian Countries - Business Wire

Gilead in Asian deal for hepatitis B drug

bizjournals (Free subscription) | 11/24/2009

Gilead Sciences Inc. and GlaxoSmithKline on Tuesday announced an agreement to commercialize Viread for the treatment of chronic hepatitis B infection in adults in five countries in Asia. (GILD) (GSK)

Gilead and GlaxoSmithKline Announce Agreement to Commercialize Viread® for Chronic Hepatitis B in Key Asian Countries

Business Wire (Free subscription) | 11/24/2009

FOSTER CITY, Calif. & LONDON--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) and GlaxoSmithKline (NYSE:GSK) today announced a licensing agreement to commercialize Viread® (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B (HBV) infection in adults in five countries in Asia. The companies’ combined commercialization activities will expand access...

WHO probing drug resistant swine flu

Reuters UK (Free subscription) | 11/24/2009

... in Wales of patients infected with H1N1 resistant to oseltamivir -- the generic name of Roche and Gilead Sciences Inc's antiviral drug Tamiflu.The patients had serious conditions that suppressed their immune systems, which can give the virus a better than usual opportunity to develop resistance, the HPA said. It said the drug-resistant strain had probably spread person to person."We have...

WHO probing spread of drug-resistant swine flu

Reuters (Free subscription) | 11/24/2009

... in Wales of patients infected with resistant to oseltamivir -- the generic name of Roche and Gilead Sciences Inc's antiviral drug Tamiflu."We have seen the reports, we need to look into them," WHO spokesman Thomas Abraham said in Geneva.The WHO has previously reported cases of the pandemic virus being resistant to oseltamivir but says these are rare.Abraham, asked whether it would be the...